Ready-to-administer injectables

Our Heparin Sodium Injection has 36 month of stability

Dear Customer, Sterinova is very pleased to announce that our Ready-to-use Heparin Sodium Injection syringe 5,000 units / 0.5 mL has now a longer stability and goes from 24 months to 36 months (room temperature). We hope that this additional stability will allow you to simplify the management of this product. We would also like

Médicament injectable en sacs de solution préremplis

HYDROmorphone Injection USP Temporary Shortage of stock

READY-TO USE SOLUTION OF HYDROMORPHONE HYDROCHLORIDE INJECTION USP, 0.4 mg / mL in 100 mL – BACKORDER NOTICE Dear Customer, Sterinova regrets to inform you of a backorder on the READY-TO USE SOLUTION OF HYDROMORPHONE HYDROCHLORIDE INJECTION USP, 0.4 mg / mL in the 100 mL format, due to an important increase in demand caused

B. Braun Melsungen AG completes acquisition of Sterinova Inc.

Saint-Hyacinthe, QC – September 29, 2021 – B. Braun Melsungen AG announces that it has acquired the minority interest of the cofounders Jean-Philippe Gentes and Bertrand Bolduc in Sterinova Inc. and now owns 100% of the company. Sterinova will continue to operate as a distinct subsidiary of B. Braun Melsungen AG. “We thank the founders

Midazolam Injection USP – Back in Stock

Dear Customer, Sterinova is more than happy to communicate that our bags of 100 mL solution of MIDAZOLAM INJECTION USP, 1 mg / mL are now available through your regular distribution channel. Our team has worked day and night to outpace the availability date of June 18, 2021 as communicated previously. We hope this good

Midazolam Injection USP Temporary Shortage of stock

Since mid-April, Sterinova has experienced a very significant increase in demand for its bags of MIDAZOLAM INJECTION USP, 100 mg / 100 mL (1 mg/mL) due to the COVID-19 situation affecting certain Canadian provinces. We have adjusted our production schedule to meet this increased demand but not quickly enough to avoid a temporary shortage of